2023
TEMPORALITY OF ISCHEMIC STROKE AND NEW-ONSET ATRIAL FIBRILLATION AND THE UTILITY OF LEFT ATRIAL STRAIN IN PATIENTS WITH CARDIAC AMYLOIDOSIS
Akintoye E, Majid M, Hanna M, Klein A. TEMPORALITY OF ISCHEMIC STROKE AND NEW-ONSET ATRIAL FIBRILLATION AND THE UTILITY OF LEFT ATRIAL STRAIN IN PATIENTS WITH CARDIAC AMYLOIDOSIS. Journal Of The American College Of Cardiology 2023, 81: 340. DOI: 10.1016/s0735-1097(23)00784-2.Peer-Reviewed Original Research
2019
Clinical and economic burden of heparin-induced thrombocytopenia in hospitalized patients undergoing percutaneous peripheral arterial interventions
Subahi A, Osman M, Adegbala O, Abubakar H, Kheiri B, Yassin A, Khalid M, Akintoye E, Eljack A, Osman K, Alkhouli M. Clinical and economic burden of heparin-induced thrombocytopenia in hospitalized patients undergoing percutaneous peripheral arterial interventions. Vascular 2019, 28: 81-86. PMID: 31382836, DOI: 10.1177/1708538119868615.Peer-Reviewed Original ResearchConceptsVenous thrombosis/pulmonary embolismAcute kidney injuryKidney injuryIschemic strokePulmonary embolismHigh riskDeep venous thrombosis/pulmonary embolismPercutaneous peripheral arterial interventionsICD-9-CM codesHospital mortality differenceProlonged hospital stayHospital-level characteristicsPeripheral arterial interventionsNational Inpatient SampleHospital outcomesHospital stayIntervention patientsAbsence of heparinBaseline characteristicsHome dischargeLonger hospitalizationArterial interventionsHospitalized patientsInpatient SampleThrombocytopenia
2018
Safety and Efficacy of Novel Oral Anticoagulants Versus Warfarin in Medicare Beneficiaries With Atrial Fibrillation and Valvular Heart Disease
Briasoulis A, Inampudi C, Akintoye E, Alvarez P, Panaich S, Vaughan‐Sarrazin M. Safety and Efficacy of Novel Oral Anticoagulants Versus Warfarin in Medicare Beneficiaries With Atrial Fibrillation and Valvular Heart Disease. Journal Of The American Heart Association 2018, 7: e008773. PMID: 29622591, PMCID: PMC6015407, DOI: 10.1161/jaha.118.008773.Peer-Reviewed Original ResearchConceptsValvular heart diseaseAtrial fibrillationMedicare beneficiariesIschemic strokeHeart diseaseNew-onset atrial fibrillationNon-vitamin K anticoagulantsGastrointestinal bleeding ratesLarge community-based samplePropensity-matched sampleCommunity-based sampleMajor bleedingNongastrointestinal bleedingCause mortalitySystemic thromboembolismVersus WarfarinPrimary outcomePropensity matchingMyocardial infarctionBleeding rateLower riskPatientsRivaroxabanWarfarinDabigatranTrends in Utilization, Mortality, Major Complications, and Cost After Left Ventricular Assist Device Implantation in the United States (2009 to 2014)
Briasoulis A, Inampudi C, Akintoye E, Adegbala O, Alvarez P, Bhama J. Trends in Utilization, Mortality, Major Complications, and Cost After Left Ventricular Assist Device Implantation in the United States (2009 to 2014). The American Journal Of Cardiology 2018, 121: 1214-1218. PMID: 29525059, DOI: 10.1016/j.amjcard.2018.01.041.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAdultAgedCardiac TamponadeDatabases, FactualFemaleHealth Care CostsHeart FailureHeart-Assist DevicesHospital CostsHospital MortalityHumansLength of StayLogistic ModelsMaleMiddle AgedMortalityMyocardial InfarctionPatient DischargePostoperative ComplicationsPostoperative HemorrhageProsthesis ImplantationRenal DialysisRespiratory Tract DiseasesStrokeSurgical Wound DehiscenceSurgical Wound InfectionUnited StatesConceptsLength of stayMajor complicationsHospital mortalityLeft ventricular assist device (LVAD) implantsVentricular assist device implantsVentricular assist device implantationAssist device implantationHospital mortality rateNational Inpatient SampleTime of dischargeCost of hospitalizationSignificant decreaseAnnual national estimatesVentricular assist deviceHospital complicationsMajor bleedingCardiac tamponadeRespiratory complicationsAdult patientsIschemic strokePostoperative infectionCF-LVADCF-LVADsDevice implantationInpatient Sample